The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Ten Common Questions (and Their Answers) About Off-label Drug Use
Open accessAbstract
The term off-label drug use (OLDU) is used extensively in the medical literature, continuing medical education exercises, and the media. Yet, we propose that many health care professionals have an underappreciation of its definition, prevalence, and implications. This article introduces and answers 10 questions regarding OLDU in an effort to clarify the practice's meaning, breadth of application, acceptance, and liabilities. Off-label drug use involves prescribing medications for indications, or using a dosage or dosage form, that have not been approved by the US Food and Drug Administration. Since the Food and Drug Administration does not regulate the practice of medicine, OLDU has become common. It occurs in every specialty of medicine, but it may be more common in areas of medicine in which the patient population is less likely to be included in clinical trials (eg, pediatric, pregnant, or psychiatric patients). Pharmaceutical companies are not allowed to promote their medications for an off-label use, which has lead to several large settlements for illegal marketing. To limit liability, physicians should prescribe medications only for indications that they believe are in the best interest of the patient. In addition, health care professionals should educate themselves about OLDU to weigh the risks and benefits and provide the best possible care for their patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“physicians may treat off-label clinical conditions and diseases for patients that respond poorly to conventional treatment, often in specific populations poorly represented in clinical trials, e.g. pediatric, pregnant or psychiatric patients (16).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [16]
In the citing paper
“Using pharmaceutical formulations (e.g. oral solution instead of capsules) or dosage (e.g. two tablets instead of one per day) not mentioned in the drug label for an indication also falls into the practice of off-label drug use (16).”
From DrugCentral 2023 extends human clinical data and integrates veterinary drugs (2023) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dworkin, R. H., O'connor, A., Audette, J. F., Baron, R., Gourlay, G. K., Haanpää, M. L., Kent, J. L., Krane, E. J., Lebel, A., Levy, R. M., et al. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0649 · Cited by 1,342
Consensus Guidelines for Managing Postoperative Nausea and Vomiting
Gan, T. J., Meyer, T. A., Apfel, C. C., Chung, F. F., Davis, P. J., Eubanks, S., Kovac, A. L., Philip, B. K., Sessler, D. I., Temo, J., et al. (2003) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000068580.00245.95 · Cited by 964
The ClinicalTrials.gov Results Database — Update and Key Issues
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M., & Ide, N. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1012065 · Cited by 838
Off-label prescribing among office-based physicians
Radley, D. C., Finkelstein, S. N., & Stafford, R. S. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.9.1021 · Cited by 711
Liebowitz, M. R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790300097013 · Cited by 576
Maher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558
Pharmacologic Closure of Patent Ductus Arteriosus in the Premature Infant
Friedman, W. F., Hirschklau, M. J., Printz, M. P., Pitlick, P. T., & Kirkpatrick, S. E. (1976) · New England Journal of Medicine · doi:10.1056/nejm197609022951003 · Cited by 497
Nightingale, S. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-3461-4.15001-9 · Cited by 444
Increasing off‐label use of antipsychotic medications in the United States, 1995–2008
Alexander, G. C., Gallagher, S. A., Mascola, A. J., Moloney, R., & Stafford, R. S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2082 · Cited by 426
Regulating Off-Label Drug Use — Rethinking the Role of the FDA
Stafford, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmp0802107 · Cited by 350
Hill, A. B. (1952) · New England Journal of Medicine · doi:10.1056/nejm195207242470401 · Cited by 256
Off-label Drug Use in Hospitalized Children
Shah, S. S., Hall, M., Goodman, D. M., Feuer, P., Sharma, V., Fargason, C. A., Hyman, D., Jenkins, K. J., White, M. L., Levy, F. H., et al. (2007) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.161.3.282 · Cited by 222
Off-Label Prescribing: A Call for Heightened Professional and Government Oversight
Dresser, R. S., & Frader, J. E. (2009) · The Journal of Law Medicine & Ethics · doi:10.1111/j.1748-720x.2009.00408.x · Cited by 158
(1972) · BMJ · doi:10.1136/bmj.2.5811.464-c · Cited by 140
Kesselheim, A. S., Mello, M. M., & Studdert, D. M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000431 · Cited by 112
Chen, H., Reeves, J. H., Fincham, J. E., Kennedy, W. K., Dorfman, J. H., & Martin, B. C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0615 · Cited by 100
Isoflurane therapy for severe refractory status asthmaticus in children
Shankar, V. R., Churchwell, K. B., & Deshpande, J. K. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0163-0 · Cited by 98
Uses of Drugs Not Described in the Package Insert (Off-Label Uses)
Committee on Drugs (2002) · PEDIATRICS · doi:10.1542/peds.110.1.181 · Cited by 96
Off-label applications for SSRIs.
Stone, K. J., Viera, A. J., & Parman, C. L. (2003) · PubMed · Cited by 89
Off-label Use of Azathioprine in Dermatology
Schram, M. E. (2011) · Archives of Dermatology · doi:10.1001/archdermatol.2011.79 · Cited by 83
Off-label medication use in adult critical care patients
Lat, I., Micek, S. T., Janzen, J. M., Cohen, H., Olsen, K. M., & Haas, C. E. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.06.012 · Cited by 65
Shifting Terrain in the Regulation of Off-Label Promotion of Pharmaceuticals
Mello, M. M., Studdert, D. M., & Brennan, T. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmhle0807695 · Cited by 59
Update on pharmacotherapy guidelines for treatment of neuropathic pain
Wallace, J. M. (2007) · Current Pain and Headache Reports · doi:10.1007/s11916-007-0192-6 · Cited by 58
Abhorring the vacuum: use of Alzheimer’s disease medications in frontotemporal dementia
Kerchner, G. A., Tartaglia, M. C., & Boxer, A. L. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.6 · Cited by 57
Wilkes, M. S., & Johns, M. Z. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050223 · Cited by 54
Phan, H., Leder, M. S., Fishley, M., Moeller, M. L., & Nahata, M. (2010) · Pediatric Emergency Care · doi:10.1097/pec.0b013e3181e057e1 · Cited by 34
Erythromycin as a prokinetic agent: Risk factors
Berthet, S., Charpiat, B., & Mabrut, J. (2010) · Journal of Visceral Surgery · doi:10.1016/j.jviscsurg.2010.06.001 · Cited by 32
Off‐Label Prescribing of Drugs in Specialty Headache Practice
Loder, E., & Biondi, D. M. (2004) · Headache The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2004.04121.x · Cited by 30
Pediatric Antidepressant Medication Errors in a National Error Reporting Database
Rinke, M. L., Bundy, D. G., Shore, A. D., Colantuoni, E., Morlock, L., & Miller, M. R. (2010) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e3181ce6509 · Cited by 29
Physicians' liability for off-label prescriptions.
Jb, R., & Pa, B. (2007) · PubMed · Cited by 24
Nightingale, S. L. (1998) · JAMA · doi:10.1001/jama.279.5.346-jfd81013-2-1 · Cited by 22
The Birth of Opioid Anesthesia
Lowenstein, E., & Raja, S. N. (2004) · Anesthesiology · doi:10.1097/00000542-200404000-00036 · Cited by 21
Pfizer settles largest ever fraud suit for off-label promotion
Ratner, M. A. (2009) · Nature Biotechnology · doi:10.1038/nbt1109-961 · Cited by 18
Hartle, A., & Malhotra, S. (2009) · BMJ · doi:10.1136/bmj.b4024 · Cited by 18
Dabigatran Etexilate: A Novel Oral Thrombin Inhibitor for Thromboembolic Disease
Bovio, J. A., Smith, S. M., & Gums, J. G. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p644 · Cited by 18
Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine
Kmietowicz, Z. (2009) · BMJ · doi:10.1136/bmj.b217 · Cited by 16
Off-Label Uses of Biologic Agents in Dermatology: A 2006 Update
Kerns, M. J., Graves, J. E., Smith, D. I., & Heffernan, M. P. (2006) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2006.08.006 · Cited by 16
Update on pharmacotherapy guidelines for the treatment of neuropathic pain
Dobecki, D., Schocket, S. M., & Wallace, M. S. (2006) · Current Pain and Headache Reports · doi:10.1007/s11916-006-0044-9 · Cited by 15
Trends in off-label β-blocker use: A secondary data analysis
Lin, H., Phan, K., & Lin, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.015 · Cited by 14
Helm, K. A. (2007) · FLASH - Fordham Law Archive of Scholarship & History (Fordham University) · Cited by 14
Abbott pays $1.6bn for promoting off label use of valproic acid
Roehr, B. (2012) · BMJ · doi:10.1136/bmj.e3343 · Cited by 10
Qureshi, Z. P., Liu, Y., Sartor, O. A., Chu, Y. H., & Bennett, C. L. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.142 · Cited by 9
Treatment Options for Female Sexual Arousal Disorder: Part II
Feldhaus-Dahir, M. (2010) · Urologic Nursing · doi:10.7257/1053-816x.2010.30.4.247 · Cited by 8
Time to Nip “Seeding Trials” in the Bud
Katz, K. A. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.3.403 · Cited by 6
Orphan Drug Act passes quarter-century milestone in fight against rare diseases
Lavine, G. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/news080054 · Cited by 6
Richardson, G. (2000) · Early Years Educator · doi:10.12968/eyed.2000.2.2.15547 · Cited by 4
Hoffmann, F., Glaeske, G., & Steuber, C. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2070 · Cited by 3
FDA allows drug firms to distribute journal articles about unapproved uses
Tanne, J. H. (2009) · BMJ · doi:10.1136/bmj.b187 · Cited by 1
Research works printed but not linked: 2
- Qureshi, 2011, Enforcement actions involving Medicaid fraud and abuse, 1996-2009, Arch Intern Med, 171, 785
- Thomas, 2012, Glaxo agrees to pay $3 billion in fraud settlement, New York Times
Cited by
Sorted by citations
Drug repurposing for antimicrobial discovery
Farha, M. A., & Brown, E. D. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0357-1 · Cited by 382
The High Cost of Cancer Drugs and What We Can Do About It
Siddiqui, M. A., & Rajkumar, S. V. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.007 · Cited by 264
Wong, J., Motulsky, A., Abrahamowicz, M., Eguale, T., Buckeridge, D. L., & Tamblyn, R. (2017) · BMJ · doi:10.1136/bmj.j603 · Cited by 221
Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018
Stark, A., Smith, P. B., Hornik, C. P. V., Zimmerman, K. O., Hornik, C. D., Pradeep, S., Clark, R. H., Benjamin, D. K., Laughon, M. M., & Greenberg, R. G. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.08.075 · Cited by 153
Nestler-Parr, S., Korchagina, D., Toumi, M., Pashos, C. L., Blanchette, C., Molsen, E., Morel, T., Simoens, S., Kaló, Z., Gatermann, R., et al. (2018) · Value in Health · doi:10.1016/j.jval.2018.03.004 · Cited by 131
Metadata
- Authors
- Wittich, C. M., Burkle, C. M., & Lanier, W. L.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Wittich, Christopher M.
- Venue
- Mayo Clinic Proceedings
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 87
- Issue
- 10
- Pages
- 982-990
- ISSN
- 0025-6196 (ISSN-L)
- PMC
- PMC3538391
- OpenAlex
- W2166119767
- Cited by
- 368
- References
- 48
- Citations by year
- 2026: 17 · 2025: 24 · 2024: 62 · 2023: 42 · 2022: 32 · 2021: 35 · 2020: 26 · 2019: 29 · 2018: 25 · 2017: 25 · 2016: 21 · 2015: 11 · 2014: 12 · 2013: 4 · 2012: 3
- FWCI
- 8.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Mayo Clinic Proceedings (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- off-label drug use, FDA-approved indications, prescribing patterns, physician liability, pharmaceutical marketing, pediatric prescribing, pregnant patients, psychiatric patients, risk-benefit assessment
- MeSH terms
- Attitude of Health Personnel, Drug Labeling, Female, Humans, Male, Patient Education as Topic, Physician-Patient Relations, Practice Patterns, Physicians', Drug Prescriptions, United States, United States Food and Drug Administration, Safety Management, Off-Label Use
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
